New pill takes on aggressive brain cancer in early trial
NCT ID NCT07464925
First seen Mar 16, 2026 · Last updated Apr 30, 2026 · Updated 7 times
Summary
This early-stage study tests an experimental pill called GLIX1 in 30 adults whose high-grade glioma (a fast-growing brain tumor) has come back or worsened after standard treatments. The main goals are to find a safe dose and check for side effects. Participants take GLIX1 daily until their disease gets worse or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Northwestern Medicine
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.